1. Ucb Pharma, S.a. (9 from 179 patents)

2. Sanofi (5 from 1,454 patents)

3. Ucb Biopharma Sprl (5 from 138 patents)

4. Ucbbiopharma Srl (5 from 109 patents)

5. Celltech R&d Limited (2 from 68 patents)

1. 11912721 - Fused pentacyclic imidazole derivatives

2. 11554122 - Fused pentacyclic imidazole derivatives as modulators of TNF activity

3. 10980814 - Fused pentacyclic imidazole derivatives as modulators of TNF activity

4. 10953019 - Fused pentacyclic imidazole derivatives as modulators of TNF activity

5. 10906919 - Fused pentacyclic imidazole derivatives

6. 10287299 - Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity

7. 10202405 - Fused pentacyclic imidazole derivatives

8. 9969728 - Tetrahydroimidazopyridine derivatives as modulators of TNF activity

9. 9550737 - TNF -α modulating benzimidazoles

10. 9309243 - Imidazopyridine derivatives as modulators of TNF activity

11. 8637491 - Thieno-pyridine derivatives as MEK inhibitors

12. 8604051 - Thieno-pyridine derivatives as MEK inhibitors

13. 8394822 - Thieno-pyridine derivatives as MEK inhibitors

14. 8350037 - Thieno-pyridine derivatives as MEK inhibitors

15. 8283359 - Thieno-pyridine derivatives as MEK inhibitors